Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

NCT04890106 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle

Interventions

DRUG: Test - Bimatoprost 0.01% Ophthalmic Solution
DRUG: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

Sponsor

Mankind Pharma Limited

Collaborators

[object Object]